Design Therapeutics (DSGN) Consolidated Net Income (2020 - 2026)

Design Therapeutics (DSGN) has 7 years of Consolidated Net Income data on file, last reported at -$21.0 million in Q1 2026.

• For the quarter ending Q1 2026, Consolidated Net Income fell 3.63% year-over-year to -$21.0 million; the trailing twelve-month figure through Mar 2026 stood at -$80.3 million (down 21.88% YoY), and the FY2025 full-year result was -$53.8 billion, down 173.08% from the prior year.
• Consolidated Net Income slipped to -$21.0 million in Q1 2026, from -$18.2 million in the prior quarter.
• In the past five years, Consolidated Net Income ranged from a high of -$13.3 million in Q1 2024 to a low of -$10.6 billion in Q4 2022.
• A 5-year average of -$703.7 million and a median of -$20.3 million in 2025 frame the typical range for Consolidated Net Income.
• Across the five-year window, Consolidated Net Income plunged 92733.1% in 2022 and soared 98.55% in 2024, its largest moves.
• Tracing DSGN's Consolidated Net Income over 5 years: stood at -$10.6 billion in 2022, then surged by 89.37% to -$1.1 billion in 2023, then soared by 98.55% to -$16.3 million in 2024, then slipped by 11.63% to -$18.2 million in 2025, then fell by 15.45% to -$21.0 million in 2026.
• Business Quant data shows DSGN's Consolidated Net Income at -$21.0 million in Q1 2026, -$18.2 million in Q4 2025, and -$19.3 million in Q3 2025.